Bucci, Marco
Savitcheva, Irina
Farrar, Gill
Salvadó, Gemma
Collij, Lyduine
Doré, Vincent
Gispert, Juan Domingo
Gunn, Roger
Hanseeuw, Bernard
Hansson, Oskar
Shekari, Mahnaz
Lhommel, Renaud
Molinuevo, José Luis
Rowe, Christopher
Sur, Cyrille
Whittington, Alex
Buckley, Christopher
Nordberg, Agneta http://orcid.org/0000-0001-7345-5151
Funding for this research was provided by:
Stiftelsen för Strategisk Forskning (RB13-0192)
Center for Innovative Medicine, Karolinska institutet
Stockholms Läns Landsting (SE) KI
Hjärnfonden
Article History
Received: 7 September 2020
Accepted: 9 March 2021
First Online: 12 April 2021
Declarations
: Data described in this report was compiled post hoc (by MB) from the clinical cohorts described in references [CitationRef removed–CitationRef removed, CitationRef removed–CitationRef removed]. Each of the studies reported was conducted with the principles of the Declaration of Helsinki, the Good Clinical Practise: Consolidated Guideline approved by the International Conference on Harmonisation and applicable national and local laws and regulations. The Ethical boards for the specific studies are listed: GE: statement of ethics compliance (and committees) in Wolk et al. 2018 [CitationRef removed]; KAROLINSKA: Ethical approval was obtained from the Regional Human Ethical Committee of Stockholm (2016-120-32); MCK: statement of ethics compliance in Sur et al. 2020 [CitationRef removed]; Le Comité d’Ethique Hospitalo-Facultaire (CEHF) des Cliniques Universitaires Saint-Luc (CUSL) approved the project from SLC under the number UCL-2010-412 (Eudra-CT: 2011-001756-12); VU University Medical Center approved the Dutch Flutemetamol study (AUMC) (reference number: 2012/302); Parc de Salut Mar (BBRC, Barcelona); BIOFINDER/INVICRO (Lund Ethics Committee, Sweden); Austin Health Human Research Ethics Committee approved the AIBL study.
: Marco Bucci, Irina Savitcheva and Agneta Nordberg have no conflicts of interest. Gill Farrar and Chris Buckley are employees of GE Healthcare. José Luis Molinuevo and JD Gispert receive doses of [<sup>18</sup>F]flutemetamol for the ALFA project, a research platform to identify early pathophysiological features of Alzheimer’s Disease (ExternalRef removed identifier NCT02685969; ExternalRef removed). Oskar Hansson receives doses of [<sup>18</sup>F]flutemetamol for the Biofinder project, which aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders for the development of early and accurate diagnostic tests, identification of novel treatment targets and to help understand the links between different pathologies and clinical symptoms (ExternalRef removed identifier NCT01208675). Chris Rowe received doses of [<sup>18</sup>F]flutemetamol for the AIBL (Australian Imaging, Biomarker and Lifestyle Flagship study set up in 2006 to which biomarkers, cognitive characteristics and health and lifestyle factors influence the development of Alzheimer’s disease (ExternalRef removed). The Dutch amyloid PET utility study of Zwan et al. [CitationRef removed] received doses of [<sup>18</sup>F]flutemetamol.